Abstract: Macroencapsulation implantation devices and containers for storing a macroencapsulation device disposed within a receptacle of a macroencapsulation implantation device as well as related methods are described. In some embodiments, a macroencapsulation implantation device may include a handle that is configured to be selectively engaged with a receptacle including a recess in which a macroencapsulation device may be disposed. In some embodiments, a container may be configured to maintain a receptacle of a macroencapsulation implantation device, and a macroencapsulation device disposed therein, in a desired pose within an internal volume of the container.

Abstract: The present invention provides devices and methods for delivering a population of cells or a therapeutic agent to a subject in need thereof.

Abstract: Provided herein are, inter alia, compositions and methods for improved production of SC-? cells in vitro. For example, provided are novel formulations and differentiation methods that result in higher cell yields and recoveries, increased numbers and relative percentages of SC-? cells, enhanced stability and shelf-life of SC-? cells, SC-islet clusters with advantageous characteristics such as reduced size and increased uniformity, improved function of the SC-? cells in vitro, and improved viability, function, and reduced immunogenicity after transplantation. The disclosed compositions and methods can be employed in the manufacture of SC-islets for human therapeutic use.

Abstract: Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic ? cell, ? cell, ? cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

Abstract: Macroencapsulation devices and related methods of manufacture are described where bonded membranes of a device may be mounted to an associated frame in an arrangement to provide stress relief between the frame and a seal perimeter of the bonded membranes. The seal perimeter may be arranged radially inward from an outer perimeter of the membranes such that when the membranes are mounted to a corresponding perimeter frame, the seal perimeter is spaced radially inwards from the frame with a unbonded portion of the one or more membranes disposed between the frame and seal perimeter.

Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of chemicals to increase the ratio of surface area to volume.

Abstract: Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic ? cell, ? cell, ? cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of channels to increase the ratio of surface area to volume.

Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of channels to increase the ratio of surface area to volume.

Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of chemicals to increase the ratio of surface area to volume.

Abstract: A method of manufacturing a macroencapsulation device includes aligning one or more membranes of the device with a frame of the device, such that a portion of the one or more membranes overlap a portion of the frame. The method also includes deforming the one or more membranes and thermoplastically deforming the frame to form mechanically interlocked regions of the membrane and the frame.

Abstract: Disclosed herein are compositions, kits, and methods related to cell therapy for a disease characterized by high blood glucose levels over a long period of time, such as diabetes. In some aspects, the methods provided herein relate to administration of non-native pancreatic cells to subject with a disease characterized by high blood glucose levels over a long period of time, such as diabetes. In some aspects, the disclosure provides pharmaceutical compositions including non-native cells.

Abstract: Provided are nucleic acid molecules, including vectors and plasmids, encoding modified u-PA polypeptides and fusion proteins containing the modified u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The nucleic acids and encoded modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.

Abstract: Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic ? cell, ? cell, ? cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

Abstract: Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.

Abstract: The present invention provides devices and methods for delivering a population of cells or a therapeutic agent to a subject in need thereof.

Abstract: The present invention provides devices and methods for delivering a population of cells or a therapeutic agent to a subject in need thereof.

Abstract: The present disclosure relates to macroencapsulation devices and related methods of manufacture where the membranes of a device may be mounted to an associated frame in a relaxed, or slack, configuration prior to filling with a desired material.

Abstract: Macroencapsulation devices and their methods of use are disclosed. In one embodiment, a macroencapsulation device may include a first outer membrane, a second outer membrane, and at least one semipermeable membrane disposed there between to form at least a primary compartment configured to house a first population of cells and a secondary compartment in fluid communication with the primary compartment through the first semipermeable membrane. In some embodiments, the flow of material into and out of the compartments of the macroencapsulation device and/or the application of an appropriate pressure differential between the compartments may be used to control the flow of filtrates, ancillary agents, and other materials between the compartments of the device when positioned in vivo.

Abstract: Nucleic acids encoding modified factor VII polypeptides, vectors and cells containing the nucleic acids, uses of the nucleic acids, methods of making the encoded polypeptides, and methods of treatment are provided. The encoded modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among the encoded modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities.